The Leukemia & Lymphoma Society | Advocacy Groups

A nutritionist discussed the difference between mainstream diets and oncology nutrition, and how patients with cancer can ensure they’re on the right track to being well-nourished throughout cancer treatment.

An expert discusses the value of Jaypirca’s recent accelerated FDA approval for relapsed/refractory mantle cell lymphoma, as well as where treatment may go next.

Two experts explain what patients need to know about the recent approval of Brukinsa for patients with chronic lymphocytic leukemia and small lymphocytic leukemia.

The past 20 years have brought great advances to advocacy groups, helping to improve patients’ quality of life. But more work is needed to raise awareness in underserved groups.

The best advocate for a patient with cancer is someone who knows exactly what they're going through, noted a multiple myeloma survivor.

New findings show that 43% of patients with certain blood cancers produced COVID-19 antibodies after receiving a third full dose of the mRNA vaccine.

An expert from the Leukemia & Lymphoma Society breaks down the effectiveness of the COVID-19 vaccine in patients with blood cancers on this episode of the “Cancer Horizons” podcast.

A three-time acute lymphoblastic leukemia survivor became a bone marrow transplant nurse and now helps other patients with the same diagnosis.

Patients with blood cancers may respond differently to doses of the COVID-19 vaccines based on the treatment they’re receiving, for example.

LLS Community is an online gathering place for patients, caregivers and healthcare professionals to share experiences and provide support.

Immune suppressing treatments — an essential component of many patients' cancer care — can blunt vaccine immune response.

Patients with relapsed/refractory, pretreated marginal zone lymphoma are now eligible for treatment with Brukinsa.

About 25% of patients with blood cancer did not produce antibodies after being vaccinated against COVID-19.

Patients with blood cancers are at a much higher risk of complications if they contract COVID-19, says an expert from the Leukemia & Lymphoma Society (LLS).

Blood shortages during the COVID-19 pandemic have forced cancer centers to get creative to ensure patients with hematologic malignancies are able to get transfusions in a timely manner.

Susan M. O’Brien, M.D., one of the nation’s foremost leukemia experts, discusses the future of frontline therapies and upcoming clinical trials associated with chronic lymphocytic leukemia.

From the American Cancer Society laying off 1,000 employees due to the economic impact of COVID-19 to former Senate Majority Leader Harry Reid announcing his cancer is in remission after receiving an experimental treatment, here’s what’s making the headlines in the cancer space this week.

Patients with blood cancers are facing unprecedented challenges to their treatment journeys as the COVID-19 pandemic continues to disrupt the cancer landscape. Which is why the Leukemia and Lymphoma Society is looking to offer its own lifeline to patients.

Two hematologist/oncologists on the LLS leadership team, and experts in the field of blood cancer, answer questions and concerns about coronavirus (COVID-19).

An expert sheds light on the latest therapies in clinical trials and promising drug combinations to thwart the aggressive disease.